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Abstract 
Objective: To summarize rates of supplement adherence in youth with inflammatory 
bowel disease (IBD) and to identify predictors and outcomes of supplement adherence.  
Methods: 49 adolescents (ages 11-18) participated. Youth completed six monthly 
assessments of adherence and supplement knowledge. Youth and parents completed 
questionnaires.  Medical record reviews provided medical and laboratory data. 
Results: Mean supplement adherence rates ranged from 32% to 44%. Predictors of 
supplement adherence included higher knowledge (for multivitamin, iron, and calcium 
adherence) higher family involvement (for iron and calcium adherence), and greater 
inflammation (via a hematological index) for multivitamin adherence.  Few relationships 
between supplement adherence and inflammation, growth, or nutritional outcomes were 
found.   
Conclusion: Supplement adherence is problematic in pediatric IBD, and predictors of 
adherence tended to be psychosocial rather than biological variables. Future research with 
larger sample sizes and assessments of supplement adherence that do not rely solely on 
patient self-report are important next steps.   
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Introduction 
Overview of IBD 
Inflammatory bowel disease (IBD) is an idiopathic autoimmune disorder, which 
causes chronic inflammation in one or more sections of the gastrointestinal tract (Gore, 
Balthazar, Ghahremani, & Miller, 1996; Hommel & Baldassano, 2010). The location of 
the inflammation, as well as the depth of inflammation in the intestinal tissue can indicate 
one of three types of IBD (Eiden, 2003; Gore et al., 1996). In Crohn’s disease (CD), 
inflammation may be present in any location from mouth to anus, yet in a majority of 
cases it is found in the terminal ileum. When diagnosing CD, the gastroenterologist will 
look for inflammation of the mucosa lining, epithelium invaded with neutrophils, and 
granuloma formation, which are indicative of CD (Eiden, 2003; Gore et al., 1996). This is 
unlike ulcerative colitis (UC), in which patients experience inflammation localized 
mainly in the mucosa of the colon and rectum (Eiden, 2003; Gore et al., 1996). Finally, 
indeterminate colitis is diagnosed when physicians cannot clearly distinguish between 
CD and UC. As summarized by Guindi and Ridell (2004), these patients often are 
diagnosed later with CD or UC. 
Patients with IBD experience a number of primary symptoms caused by the 
disease and may also experience secondary symptoms caused by IBD medication. 
Symptoms patients can experience solely from disease include diarrhea, abdominal pain, 
fatigue, loss of appetite, weight loss, anemia, stunted growth, and delayed puberty. 
Symptoms caused by maintenance medications may include: cushingoid appearance, 
weight gain, pancreatitis, and increased risk of cancer (Hommel, Denson, Crandall, & 
Mackner, 2008). Physicians apply a combination of symptoms, clinical examination, 
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laboratory indices, radiology, and endoscopy with histology to make the diagnosis, to 
assess severity, and to predict the outcome of disease (Vermeire, Van Assche, & 
Rutgeerts, 2006). Unfortunately, there is not one nutritional formulation for disease 
management that works for all patients. Instead, physicians must closely observe changes 
in patients’ weight, eating habits, and gastrointestinal (GI) symptoms (Eiden, 2003). The 
annual incidence of CD in children is 48 out of 100,000.  The annual incidence of UC in 
children is 29 out of 100,000 (Kappelman, Moore, Allen, & Cook, 2012). The large 
number of individuals afflicted by IBD demonstrates the necessity to explore the many 
challenges faced by IBD patients. 
Medication Adherence in IBD 
Medication adherence is defined as the extent to which a patient follows the 
guidelines given by their physician or health care team, regarding their medical regimen 
(Stockwell-Morris & Schulz, 1992). Across multiple pediatric conditions, nonadherence 
rates of approximately 50% are the norm, and nonadherence is considered the greatest 
cause of treatment failure among those with chronic medical conditions (Quittner, Modi, 
Lemanek, Landis, & Rapoff, 2008). Treatment regimens of IBD patients are often 
complex, involving multiple medications with varying dosing schedules and pill 
quantities, nutritional supplements, dietary modifications, medications delivered via 
infusions, clinic visits, and sometimes surgery (Hommel et al., 2008). Regimen 
complexity and other psychological factors likely combine to make treatment adherence 
challenging. Several studies have explored behavioral and family functioning in pediatric 
IBD, but few studies have focused on treatment adherence in IBD (Hommel et al., 2008). 
Existing studies of treatment adherence in pediatric IBD have focused primarily on 
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adherence to oral IBD maintenance medications (i.e., medications taken to sustain disease 
remission).  As summarized by Hommel et al., (2008), the prevalence of nonadherence to 
oral medication in IBD ranges from 38% to 66% depending on the type of medication 
and method of adherence assessment used.  
Little is known about adherence to dietary supplements among youth with chronic 
illnesses, in general, or those with IBD, in particular. Potential differences in supplement 
adherence and medication adherence may be attributed to a number of barriers unique to 
supplements (compared to IBD medications) including: larger pill size or bad taste of pill, 
knowledge of why or for what purpose they are taking the supplement, disease activity, 
experience of symptoms, and differences in child and parent involvement in 
supplementation versus primary IBD medications (Greenley, Stephens, Doughty, Raboin, 
& Kugathasan, 2010; Hommel  & Baldassano, 2010; Ingerski et al., 2010). Factors that 
influence IBD medication adherence may also influence adherence to supplements.   
  One previous study has examined supplement adherence. Kitney et al. (2009) 
investigated rates of supplement (multivitamins, vitamin D, iron, calcium, fish oil, and 
other herbal supplements) adherence and reasons given by patients for nonadherence to 
supplements.  Adherence to supplements ranged from approximately 11% to 58 %, with 
fish oil having the lowest adherence rate and vitamin D having the highest adherence rate 
(Kitney et al., 2009). Reasons participants gave for nonadherence to their supplements 
included being too busy, it involved taking too many pills, and that taking their 
supplements made them feel sick (Kitney et al., 2009). Additional research is necessary 
to validate these findings and to understand other factors that can affect supplement 
adherence in this population.  
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Relevance of Supplement Adherence in Pediatric IBD 
It is important to look at supplement adherence in adolescents because disease and 
medication side effects associated with IBD can cause nutritional deficiencies. Since 
adolescents are still developing, nutritional deficiencies may have implications for short 
and long-term health including lack of attainment of full height potential and later 
development of bone disease (Moeeni & Day, 2011). Thus, oral micronutrient 
supplementation is one medical treatment option to prevent or treat nutritional 
deficiencies.  
Nutritional Deficiencies in IBD 
Patients with IBD experience many nutritional deficiencies in specific areas, 
including iron and calcium deficiencies. Many IBD patients have one or more episodes of 
anemia, which can be a result of iron deficiency. Patients can also experience more subtle 
iron deficiencies that are below the threshold for a diagnosis of anemia (Bager al., 2011). 
Across multiple studies, it has been found that the approximate prevalence of anemia in 
IBD (30%) is only slightly lower than the approximate prevalence of iron deficiency 
(45%) (Munoz, Gomez-Ramirez, & Garcia-Erce, 2009). A lack of iron affects multiple 
essential physiological functions, the most common being oxygen transport. Iron 
deficiency can be exacerbated by chronic disease symptoms. Anemia in IBD is most 
often caused by blood loss from the bowel or decreased iron absorption due to 
inflammation of the digestive tract (Bager et al., 2011; Eiden, 2003). Hematological 
evaluations for anemia consist of a complete blood count, which includes hemoglobin 
(HGB) and hematocrit (HCT), and iron indices such as mean corpuscular volume (MCV) 
or mean corpuscular hemoglobin (MCH) (Strople & Gold, 2008; Zemel, 2008). 
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Physicians define anemia by low levels of hemoglobin or hematocrit (Strople & Gold, 
2008). 
Many physicians will delay iron therapy at time of diagnosis because anemia can 
resolve on its own when IBD symptoms are resolved (Gurram, Joeckel, & Stephens, 
2012). However, it can be difficult to correct iron deficiency without iron 
supplementation or a high iron diet (Eiden, 2003). Due to the fact that iron deficiency and 
anemia can have a large impact on adolescent quality of life, motivation to adhere to 
supplements specific to this deficiency may be higher relative to youth with no symptoms 
(Rapoff, 2010). Additionally, adherence to iron supplements can result in a decrease in 
negative symptoms and fewer laboratory abnormalities (Eiden, 2003). Therefore, iron 
supplement adherence can have profound implications for improving quality of life, 
especially if experiencing high disease activity.  
 Many patients with IBD also suffer from calcium deficiency. Inadequate intake 
and absorption of calcium is a mechanism by which skeletal disorders may develop. 
Skeletal disorders result from decreased bone density, as well as chronic inflammatory 
and autoimmune diseases (Peterlik & Cross, 2005). Decreased bone mineral density 
results from multiple factors in patients with IBD. Factors that contribute to declining 
bone mass include medications such as corticosteroids, vitamin D and calcium 
deficiency, malabsorption, and inflammation (Eiden, 2003; Thayu, Semeao, & Leonard, 
2008). Prednisone, a common drug for IBD patients, has been found to cause calcium 
loss because it leads to vitamin D resistance (Eiden, 2003). It is recommended that 
adolescents with IBD incorporate calcium and vitamin D supplementation, as well as 
exercise into their regimens to prevent bone disorders (Thayu et al., 2008). Several 
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studies have shown that calcium supplementation aids in child and adolescent bone 
formation (Thayu et al., 2008). Calcium, vitamin D, and magnesium supplementation 
decreased the relapse of a small sample of patients diagnosed with multiple sclerosis, and 
had protective effects against the development of colorectal cancer (Peterlik & Cross, 
2005). Therefore, adding calcium supplementation into an IBD regimen is essential to 
overcome the many barriers that patients face in absorbing the correct amounts of 
calcium for bone health.  
Disease Activity in IBD 
Disease activity in the context of IBD is a multidimensional construct that can be 
assessed based on serum biomarkers of inflammation, patient report, and physician 
evaluation.  The presence of inflammation is one indicator of disease activity and is 
verified through serum biomarkers levels. Level of inflammation is used for diagnosis, 
determining disease activity, predicting relapse and assessing the effect of treatment (Lok 
et al., 2008). C-reactive protein (CRP) and erythrocytic sedimentary rate (ESR) are two 
commonly used measures that become elevated in the presence of inflammation (Rees & 
Gibson, 2011). CRP is the most commonly used biomarker for indication of acute and 
chronic inflammation (Rees & Gibson, 2011). CRP is an important protein produced by 
hepatocytes during an innate immune response, indicating inflammation or infection in 
various organs (Laihia, Koskinen, Waris, & Jansen, 2005; Vermeire et al., 2006). After 
detection of inflammation, hepatocytes are up regulated by three cytokines, increasing the 
amount of CRP produced by the liver (Vermeire et al., 2006). Monitoring CRP levels is 
important for health providers to predict disease relapse, and therefore may encourage 
them to stress to patients the importance of adherence to their medical regimens.  
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Another biomarker of inflammation, which can be utilized in determining disease 
activity, is ESR. ESR is the rate at which erythrocytes migrate through the plasma 
(Vermeire et al., 2006). Normally, erythrocytes have a net negative charge and therefore 
repel one another, keeping the sedimentary rate high (Husain & Kim, 2002). Fibrinogen, 
a protein important for coagulation, forms bonds between platelets and becomes elevated 
during inflammation, which adds a positive charge to the serum (Husain & Kim, 2002). 
Therefore, during times of inflammation, erythrocytes and fibrinogen attract one another 
and sedimentary rates decrease. An abnormal ESR can be indicative of non-specific 
inflammation (Vermeire et al., 2006). Unlike CRP, changes in ESR are prolonged rather 
than immediate (Vermeire et al., 2006).  Thus, when assessing inflammation, attention to 
both CRP and ESR levels is important because CRP levels can provide valuable 
information about patient’s current level of inflammation/disease activity; whereas ESR 
levels provide information about chronic inflammation over an extended period of time.   
Other methods of assessment of disease activity in the context of IBD are patient 
report or physician report via physician global assessment (PGA), and such assessment 
may affect adherence.  Patients are accurate in identifying disease activity (Rapoff, 
2010). Asthma and cystic fibrosis patients, who have more frequent and severe 
symptoms, and those with higher disease activity, are typically more adherent to their 
medication regimens than patients with fewer, less severe symptoms and lower disease 
activity, possibly in effort to improve their predicament (Rapoff, 2010). In addition, 
patient and parental perceptions of disease severity have proved to be more useful 
predictors of adherence than those of providers (Rapoff, 2010). Physician global 
assessment is also very accurate in identifying levels of disease activity as indicated by 
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high agreement between different physician raters (Hyams et al., 1991) and high 
agreement between physician ratings and other measures of disease activity that rely on 
laboratory values, medical exam results, and patient report. As found by Sewitch et al. 
(2003), disease activity has been found to predict medication nonadherence in adult 
populations with IBD. 
Nutritional & Growth Impairment in IBD 
Growth impairment affects 15% to 40% of children with CD, while only 3% to 
10% of adolescents with UC experience growth impairment (Gurram et al., 2012; Newby 
et al., 2008). Growth impairment at time of diagnosis, or growth failure as an outcome of 
disease is more common in CD patients than in patients with UC (Moeeni & Day, 2011). 
This is mainly due to nutritional deprivation brought on by malabsorption and increased 
permeability of the ileum (Eiden, 2003; Moeeni & Day, 2011; Sturniolo, Di Leo, 
Ferronato, D’Odorico, & D’Inca, 2000; Vasseur et al., 2010). Paerregaard and Uldall-
Urne (2005) examined the effect IBD had upon growth in 99 Danish children diagnosed 
with either CD or UC. They discovered that the children with UC did not have any 
growth impairment when compared to standards. However, 50% of those with CD had a 
height below the 25th percentile for their age and sex (Paerregaard & Uldall-Urne, 2005). 
Growth impairment in IBD is often due to disease activity, including inflammation. In 
studies using mice models, it was found that 40% of growth impairment is the result of 
gut-produced inflammatory protein molecules such as Interleukin-6 and tumor necrosis 
factor-alpha, both of which can suppress levels of insulin-like growth factor (Moeeni & 
Day, 2011; Newby et al., 2008). Since IBD symptoms such as inflammation have severe 
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implications regarding growth, it is vital to explore methods such as nutritional 
supplementation that can counteract growth impairment.    
Poor nutrition and malabsorption of nutrients are other manifestations of disease 
activity. There are many causes of malnutrition and growth failure in pediatric IBD, 
including poor appetite, dietary restrictions, disease location, malabsorption, intestinal 
loss, drug-nutrient interaction, medication induced metabolic and hormonal change, and 
psychological disturbance (Eiden, 2003; Gurram et al., 2012). Nearly 90 percent of 
patients with CD experience malnutrition (Gurram et al., 2012). Poor nutrition and 
malabsorption can contribute to growth failure in IBD (Newby et al., 2008; Zemel, 2008). 
Growth status is an accurate indicator of well-being and nutritional status in adolescents 
(Zemel, 2008). Vasseur et al. (2010) investigated growth impairment and malnutrition in 
children with CD. They found that 9.5% of their sample experienced growth impairment 
and 32% experienced malnutrition. A follow up was conducted six years after diagnosis 
and it was found that 6.9% of the sample had growth impairment and 15% of the sample 
had malnutrition (Vasseur et al., 2010). Malnutrition alone is an adequate reasoning for 
supplementation in adolescents with IBD. Therefore adherence to supplementation is 
important to prevent onset of malnutrition and other morbidities.  
Predictors of Adherence 
A number of studies have examined factors associated with better adherence in 
IBD populations and among patients with other chronic medical conditions. Predictors 
can be grouped into two broad categories: biological or disease-related factors versus 
psychosocial factors.  With respect to biological factors, disease activity has been one 
factor that has been examined in relation to adherence. For example, Stockwell-Morris 
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and Schulz (1992) found that the presence of symptoms as reported by the patient was a 
predictor of nonadherence. Rapoff (2010) reviewed findings that indicated that higher 
disease activity was related to higher adherence among children with juvenile rheumatoid 
arthritis and asthma. Disease of longer duration also tended to be associated with lower 
adherence (Rapoff, 2010).  
With respect to psychological factors, both knowledge and patterns of family 
involvement have been investigated as predictors of adherence. Alm-Roijer, Stagmo, 
Uden, and Erhardt (2004) found that patients diagnosed with coronary heart disease had 
better adherence to required lifestyle changes and treatment when they had a higher 
degree of knowledge regarding the risk factors for their disease. Additionally, knowledge 
of one’s disease and regimen was found to be important but not sufficient for medication 
adherence (Hommel et al., 2013). Anderson, Auslander, Jung, Miller, and Santiago 
(1990) found higher nonadherence in adolescents with diabetes mellitus when there was a 
misunderstanding or disagreement in medical regimen responsibilities between parents 
and youth. Decreased supervision of adherence, with assumption of increased adolescent 
responsibility and involvement, was related to increased age. Similarly, when 
expectations for self-administration of asthma medication were developmentally 
inappropriate, poorer adherence was a result (Walders, Drotar, & Kercsmar, 2000). 
Therefore, there are many factors that must be considered when attempts are made to 
improve nonadherence in adolescents with IBD. 
Gaps in Current Research 
Although substantial research addresses nonadherence to oral medication in 
pediatric IBD, little current research examines rates of nonadherence to supplements in 
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the same population. This is noteworthy, given that medical professionals and researchers 
have regularly discussed the necessity for supplementation in medical regimens of IBD. 
Furthermore, little is known about predictors of higher levels of supplement adherence. 
Similarly, no one has investigated potential beneficial outcomes of higher levels of 
supplement adherence such as growth, nutrition, and disease status.  Thus, the focus of 
this study was on both biological and psychosocial predictors of adherence as well as 
biological outcomes of adherence relevant to adolescents with IBD.  
Whenever possible, multiple measures of these predictors and outcomes were 
used to acquire the most comprehensive picture of the construct. A limitation of many 
past IBD studies is the use of a wide age range of participants. To address this limitation, 
the current study focused on adolescents, a group that has an increased risk for 
nonadherence, and therefore potentially long-term deleterious health effects. In addition, 
most past studies that have examined adherence, including the Kitney study of 
supplement adherence, have collected data at just one time point (Kitney et al., 2009).  In 
contrast, this study is strengthened by its longitudinal approach, as it examines adherence 
over a relatively long period of time (i.e., 6 months), giving a more stable and 
comprehensive estimate of adherence, rather than a cross sectional approach as used by 
Kitney et al. (2009). This research also examines adherence to three of the most 
commonly used supplements in pediatric IBD, separately, rather than examining 
supplements as a single category.  
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Current Study Aims and Hypotheses 
Aim 1 
 Aim 1 was to summarize rates of multivitamin, iron, and calcium adherence 
within the sample of youth with IBD.  It was hypothesized that rates of adherence to 
supplements would be similar to or slightly lower than previously documented 
medication adherence rates in this sample (i.e., 90% or higher; Greenley et al., 2012).   
Aim 2 
Aim 2 was to examine the role of specific biological and psychological factors in 
predicting adherence to supplements in youth with IBD (both individually and 
combined). Specific predictor domains of interest include:  a) youth knowledge of the 
need for supplementation; b) baseline disease activity indices based on physician report, 
patient report, and laboratory hematological markers of inflammation; c) specific 
laboratory-based indices of nutritional deficiencies based on hematological markers of 
iron deficiency and low total calcium at baseline, and d) high levels of both parent and 
child involvement in disease management at baseline. It was hypothesized that 1) higher 
knowledge of reasons for taking the supplement would be associated with higher 
adherence during study participation; 2) higher levels of disease activity via PGA and 
patient report of disease activity, and greater proportion of hematological lab 
abnormalities indicating inflammation at baseline would be associated with higher 
adherence during study participation; 3) a greater proportion of nutrient-specific 
hematological lab abnormalities in the year preceding study participation would be 
associated with higher adherence during study participation; and 4) high levels of both 
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parent and child involvement in disease management at baseline would be associated 
with higher rates of supplement adherence during study participation. 
Aim 3 
Aim 3 was to examine relationships between supplement adherence during the 
study and disease and linear growth outcomes during the 12 months following study 
participation. Specific outcomes of interest included: a) indices of disease activity based 
on patient report at 6 month follow up, and laboratory hematological markers of 
inflammation in the 12 months after study participation; b) specific laboratory-based 
indices of nutritional deficiencies based on hematological markers of iron deficiency and 
low total calcium in the 12 months after study participation; and c) linear growth 
improvement in the 12 months following study participation. It was hypothesized that, 1) 
higher adherence during the study would be associated with lower levels of disease 
activity based on patient report of symptoms at the 6 month follow up, as well as a lower 
proportion of hematological lab abnormalities indicating inflammation in the 12 months 
following study participation; 2) higher adherence during the study would be associated 
with a lower proportion of hematological lab abnormalities in the year after study 
participation; and 3) higher adherence during the study would be associated with linear 
growth improvement in the 12 months after study participation. 
 
Methods 
Procedure 
All participants were part of a larger longitudinal study that examined adherence 
to thiopurine, an oral IBD maintenance medication, in English-speaking IBD patients 
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between the ages of 11 and 18 years who had no other chronic medical condition for 
which they needed to take daily medication. All participants included in the current 
analyses were also taking one or more supplements (i.e., multivitamin, iron, or calcium) 
daily. These three supplements were examined specifically because they are among the 
supplements that are most commonly utilized by patients with IBD, and because they 
were the supplements most readily utilized by our sample. Patients, who fit the above 
inclusion criteria, were approached at the Children’s Hospital of Wisconsin 
Gastroenterology Clinic. When they agreed to participate, children and parents provided 
consent or assent and completed the baseline questionnaires evaluating demographic 
information, disease symptoms, barriers to adherence, and youth and family functioning. 
At this time, youth also completed a validated semi-structured interview to assess their 
knowledge of and adherence to their medications and supplements, the Medication 
Adherence Measure (MAM) (Zelikovsky & Schast, 2008).  This measure was also 
completed every month by participants via phone during the 6 months of study 
participation.  Finally, patients were asked to complete questionnaires (similar to those 
completed at baseline) once more at the end of the 6 months of study participation. 
For the current analyses, medical records were also reviewed to obtain 
information about patient disease activity, linear growth, nutrition and laboratory values 
for three time periods:  one year prior to the larger longitudinal study, the 6 months 
during which time participants were enrolled in the study, and one year after the study.   
Participants 
Forty-nine of the 68 participants enrolled in the larger longitudinal study were 
included in this analytic sample. Those that were not included either withdrew from the 
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study prior to completing the 6 months of data collection, or they were not taking one of 
the three supplements of interest. Participants did not significantly differ from 
nonparticipants in age [t (66) = 0.50, p >. 05] or sex (Φ =0.09, p > .05). 
Of the 49 participants, 29 were male (59%), 45 were Caucasian (92%), and 42 
were diagnosed with Crohn’s disease (86%). Participants ranged from 11-18 years old [M 
(SD) = 14.63 years (2.03 years)]. Thirty seven (76%) patients in our sample had no 
disease activity at baseline based on PGA rating, while nine (18%) had mild disease 
activity, and three (6%) had moderate disease activity.  
 The majority of participants (92%; n = 45) were taking a multivitamin, 
while fewer were taking calcium (49%; n = 24) or iron (35% n = 17) supplements.  Most 
subjects were prescribed two supplements (59%; n = 29); fewer were taking only one 
supplement (33%; n = 16). Only 8% of the sample (n = 4) was on three supplements.  
Among the 16 youth taking one supplement, the majority (n = 13; 81%) was prescribed a 
multivitamin, with fewer prescribed iron (n = 2; 13%) or calcium (n = 2; 13%).  The 
majority of the 29 youth prescribed two supplements were taking a multivitamin and 
calcium (n = 18; 62%), while the remainder was prescribed either a multivitamin and iron 
(n = 10; 35%) or calcium and iron (n = 1; 3%).    
Measures 
Demographics 
Parents provided all demographic information at time of baseline assessment by 
completing a questionnaire. Information provided included adolescent age, gender, 
race/ethnicity, socioeconomic status, and age. 
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Adherence  
Adherence was assessed based on patient self-report on the MAM (Zelikovsky & 
Schast, 2008), a semi-structured adherence interview.  Patients were asked to report all 
supplements they were prescribed, as well as how many days in the past week they had 
missed a dose of each supplement. This information was retrieved at baseline, as well as 
at each of the monthly follow-ups. Adherence to each supplement was calculated as such: 
[(number of doses prescribed in a given week – number of doses reported missed in a 
given week) / number of doses prescribed in a given week] * 100. Each participant was 
given a total adherence score by averaging each monthly adherence score, for each 
supplement individually.  For example, if a patient were prescribed a multivitamin and 
calcium, that patient would have two adherence scores calculated:  1) 6-month 
multivitamin adherence percent; and 2) 6-month calcium adherence percent.   
Disease Activity 
Self report of symptoms. Self-reported symptoms were obtained from each of the 
participants through baseline and 6 month follow up questionnaires. The IBD Symptoms 
Checklist was created for the larger longitudinal study based on the most common 
symptoms and medication side effects seen in IBD as reported by the Crohn’s and Colitis 
Foundation of America (2013). A subset of symptoms was chosen as an index of disease 
activity in the present investigation based on those symptoms used in other measures of 
disease activity.  The specific symptoms included in the patient-report of disease activity 
in the present study were abdominal pain, nausea, vomiting, sleepiness, dizziness, 
diarrhea, loss of appetite, and fever. Patients reported if they had experienced any of the 
symptoms in the past four weeks, in a yes or no response. Yes responses were coded as 1, 
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while no responses were coded as 0. The total number of symptoms endorsed was 
summed to create a total disease activity score for each participant. Higher disease 
activity scores reflected an increased number of symptoms. 
Physician global assessment of disease activity. At enrollment, a PGA rating of 
disease activity was acquired for each patient to determine disease activity. PGA ratings 
give an indication of disease activity based on a four-point rating scale where 0 is no 
symptoms, 1 is mild, 2 is moderate, and 3 is severe disease activity. PGA ratings have 
been shown to be consistent with the Pediatric Crohn’s Disease Activity Index (PCDAI) 
and other more complex measures of disease activity (Hyams et al., 1991).  
Hematological biomarkers of inflammation. All hematological values were 
retrieved from laboratory blood draws throughout the 12 months prior to the study (pre 
study) and during the 12 months after participants had completed the study (post study). 
Each biomarker was abstracted from the patient’s medical record and analyzed separately 
for each participant. Hematological biomarkers of inflammation included CRP and ESR. 
Since participants may have had more than one lab draw during the pre study or post 
study periods, the proportions of abnormal CRP and ESR values were computed for the 
pre study and post study periods.  Proportions of abnormal CRP and ESR were calculated 
identically, but separately. First, the total number of abnormal CRP or ESR lab values 
was summed for each participant, for each biomarker, during each time interval (pre 
study or post study). Second, the total number of CRP or ESR lab values available was 
summed for each participant, for each biomarker, during each time interval (pre study or 
post study).  The proportion reflected the number of abnormal lab values divided by the 
total number of lab values available during the given time interval.  Thus, each 
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participant was given an abnormal lab proportion for each biomarker in each time 
interval that was used for analyses, resulting in 4 proportions for each participant—
Proportion of abnormal CRP values pre study, proportion of abnormal ESR values pre 
study, proportion of abnormal CRP values post study, and proportion of abnormal ESR 
values post study. 
Hematological Indices of Nutritional Status     
All nutritional outcomes were assessed via hematological lab values available in 
participant medical records. Lab values were retrieved from blood draws performed 
throughout the 12 months prior to the study (pre study) and during the 12 months after 
participants had completed the study (post study). Hematological indices included 
nutritional labs specific to calcium and iron supplementation, and biomarkers indicative 
of inflammation. The lab value that was specific to calcium supplementation was baseline 
total calcium.  Several baseline hematological indices were used for predicting iron 
deficiency including: red blood cell count (RBC), HGB, HCT, MCV, and MCH levels. A 
single iron deficiency score was calculated for each participant.  
For both calcium and iron nutritional deficiencies, a proportion was calculated to 
reflect the number of abnormal lab values compared to the total number of lab values 
available during the period (either pre study or post study).  First, the total number of 
abnormal calcium or iron-related lab values was summed for each participant during each 
time interval (pre study or post study). Second, the number of total calcium or iron-
related lab values was summed for each participant during each time interval (pre study 
or post study).  The proportion reflected the number of abnormal lab values divided by 
the total number of lab values available during the given time interval.  Thus, each 
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participant was given an abnormal lab proportion for calcium and iron in each time 
interval that was used for analyses, resulting in 4 proportions for each participant—
Proportion of abnormal iron-related values pre study, proportion of abnormal calcium 
values pre study, proportion of abnormal iron-related values post study, and proportion of 
abnormal calcium values post study. 
Knowledge 
Supplement knowledge was assessed using the MAM at baseline and at each 
monthly follow up (Zelikovsky & Schast, 2008). Participants were asked the following 
question:  “What kind of medicine is this?” for each of the supplements that they were 
prescribed.  Patients’ responses were recorded verbatim and later placed into one of three 
knowledge categories, which were developed by this student and her thesis mentor. 
Categorization was completed for each supplement separately. Categories were 
developed based on degree of knowledge of their supplements, with Category 1 being the 
least sophisticated response and Category 3 reflecting the most sophisticated response. 
Children whose responses fell into Category 1 indicated that they did not know what the 
supplement was for (i.e. “I don’t know”). Children whose responses fell into Category 2 
listed the name of supplement or described a nonspecific way the supplement was helpful 
to them (i.e. “Calcium” or “It makes me healthy”). Responses that fell into Category 3 
reported a specific way that the supplement helped their health, body, or IBD symptoms 
(i.e. “Helps my inflammation”). Two raters coded all responses and inter-rater agreement 
for response categorization was 98%. Any discrepancies were resolved by discussion. For 
the purposes of the analyses, we used the most sophisticated response given by a given 
participant over the full study interval as their measure of knowledge in the analyses.   
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Parent and Child Involvement in Supplement Taking 
Parent and child involvement was measured with the Inflammatory Bowel 
Disease Family Responsibility Questionnaire at time of enrollment (Greenley et al., 
2010). Youth answered item 24 of the questionnaire: “How involved is each family 
member in making sure you are getting a daily multivitamin or nutritional supplement”. 
Children rated their own involvement as well as their perception of their mother’s 
involvement on a 0 to 3 scale.  Families were placed into either high or low involvement 
groups. High involvement was defined as a score of 2 or 3 for both mother and child (2 is 
defined as “somewhat involved”; 3 is defined as “involved almost all the time”). If either 
individual had a low involvement rating (0 or 1), the family would be included in the low 
involvement group.  
Growth Improvement 
Growth improvement of each participant during the 12 months following study 
participation was calculated via a standard means of computing growth velocity. To 
calculate growth velocity, each patient’s height (in centimeters) was recorded at the 6-
month follow up and again at 12 months after study completion. Next, average height for 
each participant’s age and sex was abstracted from Center for Disease Control and 
Prevention (CDC) growth tables (CDC, 2009). Two z-scores were then computed: a) z1 = 
(Height at 6 month follow up) – (Average height for age and sex) / (Standard deviation of 
height from CDC); and b) z2 = (Height 12 months after completion of study) – (Average 
height for age and sex) / (Standard deviation of height from CDC). In accord with 
standard definitions used in other pediatric IBD research (Walters & Griffiths, 2008), if 
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the difference between z1 and z2 scores was ≥ 0.5 standard deviation units, that participant 
was considered to have growth improvement. 
Analytic Plan 
All analyses were performed using IBM's Statistical Package for Social Sciences (SPSS), 
version 17.0. 
Aim 1 Analyses  
To summarize rates of supplement adherence within the sample of youth with 
IBD, mean levels of supplement adherence, standard deviations, and ranges of adherence 
scores were computed for each supplement. 
Aim 2 Analyses 
Aim two sought to examine the role of biological and psychological factors in 
predicting adherence to supplements in youth with IBD (both individually and 
combined). Specific predictors of interest included:  a) knowledge of the need for 
supplementation; b) general disease activity indices; c) specific laboratory-based indices 
of nutritional deficiencies and d) family involvement.  
To examine knowledge as a possible predictor of adherence, mean differences in 
levels of adherence across the three different knowledge categories were measured using 
an ANOVA. Effect size analyses were conducted to determine the magnitude of 
differences in adherence between the three knowledge categories because of the small 
sample size. To compute effect sizes, we calculated Cohen’s d.  This statistic looks at the 
differences between two means divided by the standard deviation.  A d value of .20 = a 
small effect size, a d value of .50 = a medium effect size, and a d value of .80 = a large 
effect size.  In psychological research, most researchers agree that a medium effect size is 
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one that suggests a meaningful real-world difference between groups. We conducted 
effect size analyses because of our small sample size, which made obtaining p values < 
.05 difficult.   
To examine disease activity as a possible predictor of adherence, the following 
analyses were conducted:  a) correlations between patient report of symptoms at baseline 
and adherence; b) correlations between physician report of disease activity at baseline 
and adherence; c) correlations between proportion of hematologic markers of 
inflammation  (CRP and ESR) in the year prior to study participation and adherence 
during the study for each supplement separately.  
To examine the possible association between proportion of nutrition related 
laboratory abnormalities in the year before study participation and adherence, 
correlations were run to test for a significant relationship. Specific nutritional lab 
abnormalities investigated were: total calcium, HGB levels, RBC count, HCT levels, 
MCV, and MCH levels. 
Finally, correlations were run to examine the possible relationship between family 
involvement and supplement adherence during study participation, for each supplement 
separately. Participants were grouped into one of two categories based on family 
involvement (high involvement of both mother and child or lack of high involvement of 
both mother and child).  
To examine the combined influence of multiple biological and psychological 
factors on supplement adherence, regression analyses were conducted.  Regression 
models containing multiple independent variables were examined as predictors of 
supplement adherence. Predictor variables were included in these regression models if 
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they were correlated at r = .30 or higher with adherence (the equivalent of a medium 
effect size). Separate regression analyses were conducted for each of the three 
supplements. 
Aim 3 Analyses 
The goal of Aim 3 was to examine relationships between supplement adherence 
during the study and disease and growth outcomes during the 12 months following study 
participation. Specific outcomes of interest were: a) indices of disease activity; b); 
presence of hematologic lab abnormalities associated with specific nutrient deficiencies; 
and c) growth improvement.  
To examine the possible relationship between adherence during the study with 
disease activity after study participation, correlations were run between adherence during 
the study and youth reported symptoms at 6 month follow up. Correlations were also run 
between adherence during the study and proportion of hematologic markers of 
inflammation (CRP and ESR) in the year following study participation. 
To study possible associations between adherence during study participation and 
proportion of nutritional lab abnormalities in the 12 months following study participation, 
two correlations were run. The first correlation examined associations between the 
proportion of calcium specific lab abnormalities and adherence rates. The second 
correlation examined associations between the proportion of iron specific lab 
abnormalities and adherence rates. Specific nutritional lab abnormalities investigated 
were: total calcium, HGB levels, RBC count, HCT levels, MCV, and MCH levels.  
Finally, correlations were run between adherence during study participation and 
growth improvement in the 12 months following study participation to test for possible 
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significant relationships. For these analyses, participants were coded as showing growth 
improvement versus no evidence of growth improvement.   
For all analyses related to Aims 2 and 3, each supplement was examined 
separately. In addition, because of the small sample size, we did not rely solely on p 
values to determine significance of findings (since with a small sample size, we were at 
an increased risk of making a Type I Error).  Rather, any findings meeting criteria for a 
medium effect size (e.g., bivariate or semi-partial correlations of .30 or higher) were 
considered to be meaningful findings.  
 
Results 
Aim 1 Results 
Aim 1 summarized rates of adherence to multivitamin, iron, and calcium 
supplements (Table 1).  Mean adherence to multivitamin, iron, and calcium regimens 
ranged from 32% to 44%.  Mean multivitamin adherence was 36.47% + 30.77 SD, mean 
iron adherence was 44.19% + 34.86 SD, and mean calcium adherence was 31.67% + 
27.85 SD in the sample. Supplement adherence was well below average adherence of 93-
98% to prescribed oral medication in a similar population (Greenley et al., 2012).  Thus, 
our finding of mean supplement adherence rates of 32% to 44% was not consistent with 
the hypothesis that supplement adherence rates would be similar to or slightly lower than 
published oral medication adherence rates. Instead, they were much lower than oral 
medication rates.  
 
 
MICRONUTRIENT	  SUPPLEMENTATION	  IN	  IBD	  	  	  	  	  	   25	  
Table 1.   
Mean, Standard Deviation, and Range Statistics for Rates of Adherence to Supplements  
 
Supplement  X SD Range N 
Multivitamin 36.47 30.77 0-93.88 45 
Iron 44.19 34.86 0-100 17 
Calcium 31.67 27.85 0-91.84 24 
 
Aim 2 Results 
Aim 2 examined the role of specific biological and psychological factors in 
predicting adherence to supplements in youth with IBD. We examined relationships 
between predictors and adherence both individually and combined. Specific predictors 
examined included: a) youth knowledge of the need for supplementation; b) baseline 
disease activity indices based on physician report, patient report, and laboratory 
hematological markers of inflammation; c) specific laboratory-based indices of 
nutritional deficiencies at baseline, and d) level of parent and child involvement in 
disease management at baseline (coded as high or low involvement). Because of the 
small sample size, we did not rely solely on p values to determine significance of findings 
(since with a small sample size, we were at an increased risk of making a Type I Error).  
Rather, any findings meeting criteria for a medium effect size (e.g., correlations of .30 or 
higher) were considered to be meaningful findings.  
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Knowledge and Adherence 
One-way ANOVAS were conducted to examine the relationship between 
knowledge (categorized into low, moderate, and high groups) and adherence to 
multivitamin, iron, and calcium supplements (Figure 1). Knowledge had a significant 
main effect on adherence for all three supplements.  First, knowledge had a main effect 
on multivitamin adherence [F (2, 42) = 21.29, p < .01]. Follow up analysis results 
showed that those with low knowledge had lower multivitamin adherence (M = 7.00% 
SD = 14.95), than those with moderate (M = 44.71% SD = 26.38; d = 1.64), or those with 
high knowledge (M = 70.91% SD = 14.79; d = 4.29). Additionally, those with moderate 
knowledge had significantly lower adherence than those with high knowledge (d = 1.06). 
All effect sizes that examined differences in adherence between the three knowledge 
groups were large in magnitude. These findings were consistent with the hypothesis that 
higher knowledge of multivitamin supplement would be related to better adherence to a 
multivitamin supplement.   
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Figure 1.  Mean rates of adherence to vitamin and mineral supplements for the total sample and 
by subgroups of participants based on supplement knowledge category.  Standard deviations are 
represented in the figure by the error bars attached to each column.    
 
Knowledge also had a main effect on adherence to iron supplements [F (2,14) = 
5.48, p < .05] Results indicated that those with low knowledge had lower adherence (M = 
15.36% SD = 22.93), than those with moderate (M = 45.71% SD = 32.95; d = 1.16), or 
those with high knowledge (M = 65.24% SD = 29.53; d = 1.85; Figure 1). The moderate 
knowledge group also had significantly lower adherence compared to the high knowledge 
group (d = 0.64). Effect sizes were found to be medium and large. These results support 
the hypothesis that higher knowledge of iron supplementation would be related to higher 
adherence to an iron supplement.  
Finally, knowledge had a main effect on calcium supplement adherence [F (2,21) 
p < .05].  Analyses indicated that those with low knowledge had lower adherence (M = 
7.14% SD = 17.50), than those with moderate (M = 39.68% SD = 30.00; d = 1.26), or 
those with high knowledge (M = 40.02% SD = 23.16; d = 1.55; Figure 1). Effect sizes 
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were large in magnitude, and therefore support the hypothesis stating higher calcium 
supplement knowledge is related to higher calcium supplement adherence. However, only 
a small effect size was found for the difference between the moderate and high 
knowledge group (d = 0.01) and therefore this comparison did not support the hypothesis. 
Disease Activity and Adherence 
With respect to disease activity as a predictor of adherence during the study, we 
used three different measures of disease activity: 1) baseline self-report of disease-related 
symptoms; 2) baseline physician’s global assessment of disease activity; and 3) baseline 
laboratory hematological indicators of inflammation. Only one meaningful correlation 
between disease activity and adherence was found.  Specifically, a meaningful correlation 
was found between abnormal CRP levels and multivitamin adherence (r = .43, p > .05), 
such that higher inflammation prior to the study predicted better multivitamin adherence 
during the study.   
Correlations between self-reported symptoms and multivitamin adherence were 
not significant (r = -.17, p > .05). Correlations between self-reported symptoms and iron 
adherence were not significant (r = .28, p > .05).  Correlations between self-reported 
symptoms and calcium adherence were not significant (r = .24, p > .05). Correlations 
across all three supplements were small in magnitude. Thus, the lack of significant 
findings was not due to the small sample size.  The hypothesis that a higher number of 
self-reported symptoms of disease activity will predict higher adherence was not 
supported.  
Additionally, no significant correlations were found between baseline physician’s 
global assessment of disease activity and supplement adherence for all three supplements 
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(multivitamin adherence r = -.09, p > .05; iron adherence r = -.02, p > .05; and calcium 
adherence r = .24, p > .05). All three of these correlations failed to meet the cut off for a 
designation of a small effect size and thus were found to be or less than small in 
magnitude. Therefore, the hypothesis that physician’s assessment of disease activity was 
associated with supplement adherence was not supported.  
 Regarding inflammation as a predictor of adherence to multivitamin, calcium, and 
iron adherence, two different baseline hematological indices of inflammation were used: 
CRP and ESR. No significant correlations were found between abnormal CRP levels and 
iron adherence (r = .24, p > .05), or between abnormal CRP levels and calcium adherence 
(r = .01, p > .05). Correlations between abnormal CRP levels and iron adherence, and 
abnormal CRP levels and calcium adherence were small effect sizes. No significant 
correlations were found between abnormal ESR and iron adherence (r = .24, p > .05), 
multivitamin adherence (r = .02 p > .05) or calcium adherence (r = -.04, p > .05). These 
correlations were small or less than small in effect size. Taken together, results 
examining CRP and ESR as measures of inflammation offered little support for the 
hypothesis that with an increased proportion of abnormal inflammatory markers present 
at baseline, there would be increased adherence to the three supplement categories 
throughout the study. Specifically, in only one of six analyses this hypothesis was 
supported. 
Laboratory-Based Nutritional Abnormalities and Adherence 
The presence of nutritional abnormalities the year prior to study participation was 
used to predict adherence to iron and calcium supplements during study participation. 
Nutritional abnormalities included factors indicative of iron deficiency (which were 
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correlated with iron adherence only) and total calcium (which were correlated with 
calcium adherence only). Regarding factors indicative of possible iron deficiency, the 
following hematological indices were used: HGB, RBC, HCT, MCV, and MCH. 
Correlations were run using the proportion of abnormal laboratory indices in the year 
prior to enrollment as the predictor. No significant correlation was found between 
presence of abnormal iron labs and iron adherence (r = -.12, p > .05). These findings did 
not support the hypothesis that those with a greater proportion of abnormal iron labs 
would have better adherence to iron supplements during the study.  
Finally, patients’ proportion of abnormal calcium lab values during the one-year 
before enrollment was examined as a possible predictor of calcium adherence. It was 
found that those with low total calcium one year prior to the study were not more likely 
to have higher adherence to a calcium supplement during the study (r = .27, p > .05). 
This finding did not support the hypothesis that those with a greater proportion of 
abnormal calcium labs present in the year prior to the study would have better adherence 
to their calcium supplement during the study.  
Family Involvement and Adherence 
Correlations were examined between youth and mother involvement at baseline 
and adherence to multivitamin, iron, and calcium supplements, respectively. Meaningful 
correlations were found between involvement and both iron adherence (r = .59, p < .05) 
and calcium adherence (r = .33, p > .05), while no meaningful correlation was found 
between multivitamin adherence and involvement (r = .29, p > .05); although the latter 
nearly reached criteria for a medium effect size and for statistical significance. The 
correlation between iron and involvement was medium in magnitude, and the correlation 
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between calcium adherence and involvement was small in magnitude. This supported the 
hypothesis that the group of families with high youth and mother involvement in 
administration of supplements would have higher adherence to those supplements 
compared to families in which one or both family members had low levels of 
involvement.  
Regression Analyses  
Linear multiple regression analyses were run in order to examine the combined 
impact of several of the above independent variables on supplement adherence. Analyses 
were run with all independent variables entered using simultaneous entry. Only 
independent variables with correlations of .30 or larger (the equivalent of medium effect 
sizes) with the dependent variable were chosen for inclusion in the regression analyses. 
Three regressions were run in total, one for each supplement dependent variable (i.e., 
multivitamin, iron, and calcium). 
Results of a regression analysis in which multivitamin adherence was the 
dependent variable showed that multivitamin knowledge and proportion of abnormal 
CRP levels combined contributed 48.4% of the variance to the predication of 
multivitamin adherence, a statistically significant finding (Multiple R = .70; F (12, 11) = 
5.16, p < .05; Table 2). After controlling for the impact of knowledge, proportion of 
abnormal CRP levels were not a statistically significant predictor of multivitamin 
adherence (β involvement = .35; t = 1.59, p > .05). However, when controlling for the 
effect of CRP abnormality, knowledge was a statistically significant predictor of 
multivitamin adherence (β involvement = .55; t = 2.52, p < .05). Examination of effect 
sizes by looking at the squared semi-partial correlations showed a medium effect size for 
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multivitamin knowledge (sr2  = .30) and a small effect size for abnormal CRP (sr2  = .12). 
These results support the hypothesis that combining independent variables would account 
for even more variance in multivitamin adherence than each of the independent variables 
alone (Table 2). 
 
Table 2.   
Predictors of Multivitamin Adherence 
Independent Variable B β t sr2 
Multivitamin Knowledge 28.37 .55 2.52 .30 
 
Abnormal CRP Lab Value 32.09 .35 1.59 .12 
     
    R = .70 
    R2 = .48 
    F = 5.16* 
 
*p<.05; **p<.01; ***p<.001 
 
For the regression analysis in which iron adherence was the dependent variable, 
iron knowledge and family involvement variables combined contributed 50.3% variance 
to the prediction of iron adherence, a statistically significant result (Multiple R = .71; F 
(2, 13) = 6.59, p < .05; Table 3).  After partialling out the impact of family involvement, 
knowledge was not a statistically significant predictor of iron adherence (β knowledge = 
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.48; t = 2.02, p > .05). After partialling out the impact of knowledge, family involvement 
was not a statistically significant predictor of iron adherence (β involvement = .32; t = 
1.34, p > .05). Examination of effect sizes by looking at the squared semi-partial 
correlations showed a small effect size for knowledge (sr2 = .16) and a less than small 
effect size for involvement (sr2 = .07). These results support the hypothesis that 
combining independent variables would account for even more variance in the prediction 
of iron adherence than each of the independent variables alone. 
 
Table 3.   
Predictors of Iron Adherence 
Independent Variable    B   β      t sr2 
Iron Knowledge 18.49 .48 2.02 .16 
Mother and Child Involvement 28.24 .32 1.34 .07 
     
    R = .71 
    R2 = .50 
    F = 6.59* 
 
*p<.05; **p<.01; ***p<.001 
 
In a regression analysis in which calcium adherence was the dependent variable, 
calcium knowledge and family involvement variables combined accounted for 18.9% of 
the variance in the predication of calcium adherence. This finding was statistically 
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significant (Multiple R = 0.55; F (2, 21) = 4.61, p < .05; Table 4). After controlling for 
the effect of knowledge, family involvement was not a statistically significant predictor 
of calcium adherence (β involvement = .34; t = 1.87, p > .05). However, after controlling 
for family involvement, knowledge was a statistically significant predictor of calcium 
adherence (β involvement = .44; t = 2.42, p < .05). Effect sizes, determined by examining 
squared semi-partial correlations, were small for both calcium knowledge (sr2 = .19) and 
family involvement (sr2  = .11). These results support the hypothesis that combining 
independent variables would account for even more variance in calcium adherence than 
the each of the independent variables alone. 
 
Table 4.   
Predictors of Calcium Adherence 
Independent Variable B β t sr2 
Calcium Knowledge 15.37 .44 2.42 .19 
 
Mother and Child Involvement 20.41 .34 1.87 .11 
     
    R = .55 
    R2 = .31 
    F = 4.61* 
 
*p<.05; **p<.01; ***p<.001 
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Aim 3 Results 
Aim 3 examined relationships between supplement adherence during the study 
and disease and growth outcomes during the 12 months following study participation.  
Specific outcomes of interest included: a) indices of disease activity; and b) presence of 
hematologic lab abnormalities associated with specific nutrient deficiencies. Because of 
the small sample size, we did not rely solely on p values to determine significance of 
findings (since with a small sample size, we were at an increased risk of making a Type I 
Error).  Rather, any findings meeting criteria for a medium effect size (e.g., correlations 
of .30 or higher) were considered to be meaningful findings. 
Disease Activity and Adherence  
When examining the relationship between supplement adherence during the study 
and disease activity outcomes, we used two different measures of disease activity: 1) 
presence of self-reported disease-related symptoms at the six month follow up; and 2) the 
proportion of abnormal hematological indicators of inflammation collected during the 12 
months following study participation. No significant correlations were found between 
supplement adherence and self-reported disease symptoms for any of the three 
supplements (multivitamin adherence r = -.09, p > .05; iron adherence r = -.01, p > .05; 
and calcium adherence r = .16, p > .05). Correlations between multivitamin adherence 
and iron adherence with self-reported disease activity did not meet the cut off for a small 
effect size. The correlation between calcium adherence and self-report of disease activity 
was small in magnitude. These findings did not support the hypothesis that higher 
adherence would be related to the outcome of fewer self-reports of disease-related 
symptoms at the six-month follow up. 
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 Correlations were also run to examine the relationship between supplement 
adherence during the study and indicators of disease inflammation as outcomes. The 
proportions of two different hematological indices of inflammation, CRP and ESR, 
collected during the year following study participation were used in analyses. A 
meaningful correlation was found between calcium adherence and proportion of 
abnormal CRP levels (r = .35, p > .05), yet no significant correlations were found 
between multivitamin adherence and proportion of abnormal CRP levels (r = -.03, p > 
.05), or between iron adherence and proportion of abnormal CRP levels (r = -.07, p > 
.05). The correlation between calcium adherence and proportion of abnormal CRP levels 
was found to be medium in magnitude. Correlations between multivitamin adherence and 
proportion of abnormal CRP levels, and iron adherence and proportion of abnormal CRP 
levels did not meet the threshold for a small effect size. These findings did not support 
the hypothesis that higher adherence would be related to a lower proportion of abnormal 
CRP levels in the year after study participation. 
No significant correlations were found between multivitamin adherence and 
proportion of abnormal ESR levels (r = .18, p > .05) or between calcium adherence and 
proportion of abnormal ESR levels (r = .27, p > .05), yet the correlation between iron 
adherence and proportion of abnormal ESR levels was meaningful (iron adherence r = -
.48, p > .05). Correlations between multivitamin adherence and proportion of abnormal 
ESR levels, as well as between calcium adherence and proportion of abnormal ESR 
levels met the threshold for a small effect size. Correlations between iron adherence and 
proportion of abnormal ESR levels were found to be medium in effect size. These results 
only partially supported the hypothesis that with an increased adherence to the three 
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supplement categories throughout the study, the proportion of abnormal ESR present in 
the year after the study would decline. 
Adherence and Laboratory-Based Nutritional Outcomes 
Adherence scores to iron and calcium supplements were used to predict the 
presence of select nutritional abnormalities in the 12 months after study completion. 
Nutritional abnormalities included factors indicative of iron deficiency and low total 
calcium, which were identified by several laboratory indices. Regarding factors indicative 
of possible iron deficiency, I examined the following hematological indices as outcomes 
of iron adherence: HGB, RBC, HCT, MCV, and MCH. Correlations were run using the 
proportion of abnormal laboratory indices during the 12 months after study completion. 
A meaningful correlation was found between iron adherence and proportion of abnormal 
iron labs (r = -.34, p > .05). This correlation was found to have a medium effect size. This 
finding supported the hypothesis that those with higher adherence during study 
participation would be less likely to have abnormal iron labs 12 months after study 
participation.  
Finally, the relationship between patients’ calcium adherence during the study and 
the proportion of total calcium lab abnormalities during the 12 months after study 
participation was examined. Results suggested that there was no significant association 
between calcium adherence during the study and proportion of abnormal calcium lab 
values in the 12 months after the study (r = -.06, p > .05). This finding did not support 
the hypothesis that those who have higher calcium supplement adherence during study 
participation are more likely to have fewer low total calcium labs in the 12 months after 
study participation.  
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Growth Improvement  
Adherence scores to multivitamin, iron, and calcium supplements during study 
participation were used to predict the presence of growth improvement in the 12 months 
following study participation. Correlations were run between adherence and growth 
improvement (coded as either a presence or absence of growth improvement). It was 
found that higher adherence to any of the three supplements during the study did not 
predict growth improvement in the 12 months following the study (multivitamin 
adherence r = .04, p > .05; iron adherence r = .17, p > .05; and calcium adherence r = 
.03, p > .05). Since growth improvement may not be expected when disease activity is 
present, we conducted additional analyses with only those who had no disease activity.  
In these analyses, no significant relationship was found between increased adherence to 
any of the three supplements and growth improvement following study participation 
(multivitamin adherence r = -.06, p > .05; iron adherence r = .19, p > .05; and calcium 
adherence r = .00, p > .05).  
 
Discussion 
The current study was designed to examine rates of adherence to dietary 
supplements among youth with IBD and also to examine predictors and outcomes of 
supplement adherence.  Rates of supplement adherence were found to be quite low in the 
present study (32% to 44%). Supplement adherence rates were significantly lower than 
those of medication adherence rates of the same population (i.e., > 90%); however these 
rates were comparable to supplement adherence rates found by Kitney et al. (2009). 
There are many reasons that supplement adherence rates may have been lower than 
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medication adherence rates. One explanation relates to the importance that families and 
health providers might place on supplements compared to prescription medications.  
Children and parents may not consider supplementation to be as important to the child’s 
medical regimen as are their medications. Additionally, health care providers may not be 
placing a large emphasis on the importance of supplementation. Finally, limited 
knowledge of the benefits of supplements may interfere with supplement adherence. 
Families may not know the benefits supplements can provide them in the long term and 
may not notice any short-term benefits of taking the supplements. We found that children 
with higher knowledge of the benefits of supplements were more likely to be adherent to 
the supplements (Figure 1).  Many of the prescription medications that children take for 
IBD are small pills that are easy to swallow.  In contrast, children may be more opposed 
to taking supplements that can sometimes be large, odorous, and cause stomach upset if 
taken without food. Also, it is possible that families may be opposed to increasing the 
complexity of their medical regimen by adding supplements and may choose to focus just 
on prescription medication, viewing the supplements as less important. The large 
discrepancy between rates of adherence to supplements compared to rates of oral IBD 
maintenance medication adherence from the same sample, point out the importance of 
examining supplement adherence separately from oral medication adherence (Table 1).   
Although supplement adherence overall was low, several meaningful predictors of 
supplement adherence were found. Predictors included higher knowledge (for 
multivitamin, iron, and calcium adherence), high levels of youth and mother involvement  
(for iron and calcium adherence), and baseline CRP levels (for multivitamin adherence) 
(Table 2; Table 3; Table 4). Finding knowledge as a predictor of adherence supports the 
MICRONUTRIENT	  SUPPLEMENTATION	  IN	  IBD	  	  	  	  	  	   40	  
findings of Alm-Roijer et al. (2004) in which higher knowledge was also found to be a 
predictor of adherence among coronary artery disease patients. Additionally, finding 
family involvement as a meaningful predictor of supplement adherence is similar to the 
findings of Anderson et al. (1990) in which high levels of parent and youth involvement 
promoted more optimal diabetes management. In previous studies high disease activity 
has not been shown to predict adherence to oral maintenance medications in IBD 
(Greenley et al., 2010), although measures used to indicate disease activity in previous 
studies were physician global assessment ratings, rather than CRP levels. Perhaps 
associations between CRP levels and multivitamin adherence were found in the current 
study because CRP levels measure changes intravenously and may predict future disease 
activity that may not yet be detectable by physicians or patients on the basis of a physical 
exam or report of current symptoms. Overall, fewer significant predictors were identified 
than were expected. This may be due to the small sample size or low disease activity in 
the sample.  In addition, the majority of meaningful predictors of adherence were mainly 
psychosocial in nature. It is possible that because participants tended to have low levels 
of disease activity and few disease symptoms, it was harder to find relationships between 
biological factors and adherence than if the sample had had larger rates of disease 
activity.   
Several relationships between adherence and disease-related outcomes were found 
in the current study.  Specifically, higher calcium adherence during the study predicted a 
greater proportion of abnormal CRP levels during the twelve months following study 
participation, a finding contrary to prediction.  In addition, higher iron adherence during 
the study was found to predict a lower proportion of abnormal ESR levels in the year 
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following study participation. Similarly, both higher iron and calcium supplement 
adherence predicted fewer nutrient-specific lab deficiencies in the twelve months 
following study participation. Fewer significant outcomes of supplement adherence were 
identified than were expected. This may be again due to low levels of disease activity and 
few problems with growth in the overall sample.  Therefore, there may have been little 
room for improvement of disease activity, nutrition status, or growth as a result of better 
supplement adherence. It is also possible that adherence to supplements alone is not 
enough to promote better disease-related outcomes.  It is possible that the combination of 
good adherence to the IBD treatment medications and good adherence to supplements 
might be more important in predicting positive outcomes than supplement adherence 
alone.  Additionally, regarding our measure of growth improvement, participants’ 
parental height was not considered before analyses for growth impairment were 
conducted. There also was no consideration for participants who have finished puberty 
and have completed growth.   
Limitations 
In addition to the limitations mentioned above, there are several other noteworthy 
limitations that should be acknowledged. Supplement adherence rates were abstracted 
from a study with alternative goals, rather than from a study that was primarily designed 
to investigate supplement adherence. Because of this, only self- report measures of 
supplement adherence were available, rather than more sophisticated measures of 
adherence or even multiple measures of supplement adherence. In addition, it may have 
been important to consider each participant’s time since diagnosis as a factor. Patients 
who were enrolled closer to the time of their diagnosis may have more nutritional 
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deficiencies and more disease activity than patients who were diagnosed a long time ago. 
This may be due to less time on maintenance medications to get their disease under 
control. In addition, in this sample, a majority of participants had low levels of disease 
activity and few nutritional abnormalities overall. Having a more diverse sample with 
respect to levels of disease activity and malnutrition could help to improve the chances of 
finding a significant relationship between adherence and these disease factors. Similarly, 
children who are newly diagnosed may not have had sufficient time to experience catch 
up growth common in adolescents soon after their disease has been controlled via 
medication. Newly diagnosed patients who have never had a medical regimen before may 
also have more difficultly remembering or scheduling taking their medications and 
supplements compared to those who have been diagnosed for a longer period of time. 
Future Research Directions 
In the future, a larger sample will allow researchers to get a better understanding 
of the overarching predictors and outcomes being examined here. A larger sample can 
maximize probability of finding statistically significant relationships between variables, 
while limiting the influence of outliers. A larger sample also more accurately reflects the 
IBD population so it helps the results generalize better. Adherence can also be measured 
in a more precise and accurate way other than self-report. Self-report in adolescents 
leaves room for honest miscalculation or over estimation of doses missed. Perhaps the 
use of a software pill bottle to track particular supplements can be implemented. Changes 
could also be made to the sample to include only adolescents who have not yet reached 
the end of puberty. This would allow for growth improvements to be observed in all 
participants.  
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Other variables that may be beneficial to examine could include: time since 
diagnosis, number of medical or emergency visits due to disease, knowledge of 
nutritional abnormality, knowledge of status of disease activity, body mass index 
percentile, and results of dual-energy X-ray absorptiometry (DEXA) scans. Having 
participants who have a greater range of times since diagnosis will aid in determining if 
this is an important variable in that should be controlled for when examining disease 
activity and growth improvement. Acquiring documentation of number of medical or 
emergency visits may be another factor in determining disease severity. High disease 
activity is often indicated when children have a relapse, sometimes requiring 
hospitalization or extra clinical visits. If children have knowledge regarding the severity 
of their disease or knowledge regarding their nutritional abnormality detected via blood 
draws, they may be more motivated to take their supplements. This might be especially 
important for supplement adherence, where the purpose of taking the supplement isn’t 
easily observable. Additionally, patients who receive DEXA scans will have greater 
information regarding their bone density status, which may motivate children to adhere to 
their calcium supplement specifically.  Finally, body mass index percentile can aid in 
determining an adolescent’s malnutrition status, as many children lose weight as a result 
of malabsorption and a need for higher caloric intake. 
Treatment Implications 
Since multiple studies, including the current study, have shown that supplement 
adherence rates in this population are quite low, health professionals should place a larger 
emphasis on adherence to supplements in the context of the routine outpatient IBD clinic 
appointments. Medical staff should take time during routine check ups to educate their 
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patients, especially adolescents, on the supplements suggested to them. It is vital to stress 
the importance and reasons for adhering to supplements particularly because knowledge 
has been shown to be a significant predictor of higher adherence. Similarly, because 
family involvement was shown to be a predictor of higher adherence, parents may also 
need to be educated on how supplements can aid in improving their child’s condition, and 
how supplements can be beneficial to them overall. In addition, providers can work with 
families to make sure both parents and youth are very involved in supplement 
administration as a possible way to improve adherence.  One-to-one counseling with a 
trusted health provider has been shown in several studies including one by Stockwell- 
Morris & Schulz (1992) to be an effective way to improve adherence. 
In conclusion, this study discovered that overall adherence rates to multivitamin, 
calcium, and iron supplements were quite low for adolescents with IBD, and much lower 
than rates of oral IBD medication in this same sample.  Salient predictors of supplement 
adherence tended to be psychosocial rather than biological in nature, with knowledge 
being the most consistent predictor of adherence during study participation. Iron 
adherence was associated with biological outcomes including lower proportion of 
abnormal ESR values and fewer iron-related nutrient deficiencies.  However, adherence 
to supplements did not significantly impact growth in the year following study 
participation. Although this study provides some initial information about supplement 
adherence, additional research with larger and more diverse samples is needed to more 
fully understand the importance of supplement adherence in the context of pediatric IBD.  
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